查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1873985

抗凝血逆轉藥物市場

Anticoagulant Reversal Drugs Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

預計到2031年，抗凝血逆轉藥物市場規模將從2024年的14.3億美元成長至24.4億美元，2031年至2031年的年複合成長率（CAGR）為10.08%。創新產品的推出預計將成為抗凝血逆轉藥物市場的重要趨勢。

抗凝血逆轉藥物市場分析

近年來，抗凝血藥物在預防和治療各種心血管疾病方面應用廣泛，包括肺栓塞（PE）、深部靜脈栓塞（DVT）、心房顫動（AF）、機械心臟瓣膜相關血栓形成以及急性冠狀動脈綜合症。然而，這些藥物的廣泛使用會帶來大小出血的風險，可能導致住院和急診。當患者接受包含抗凝血藥物和抗血小板藥物或雙重抗血小板藥物的合併治療時，這種風險會更高。單獨使用華法林和阿斯匹靈時，出血風險最高。因此，抗凝血逆轉藥物對於降低出血風險至關重要。心房顫動（AFib）盛行率的不斷上升和卒中事件的增加預計將推動旨在改善患者預後的新療法的研發。

抗凝血逆轉藥物市場概覽

根據美國疾病管制與預防中心（CDC）統計，美國每年有超過45.4萬人因心房顫動住院治療，約15.8萬人因此死亡。心房顫動的發生率隨年齡增加而增加，而高血壓在老年族群中也更為常見，約五分之一的心房顫動病例是由高血壓引起的。預計未來十年，老年人口的成長將推動抗凝血逆轉藥物的需求增加。

戰略洞察

抗凝血逆轉藥物市場的促進因素與機遇

神經退化性疾病和言語障礙發生率不斷上升

抗凝血逆轉藥物在出血性中風的治療中發揮著至關重要的作用，它們能夠減少持續出血並促進組織恢復。卒中的發生率正在上升，尤其是在中低收入國家。根據卒中意識基金會報告，美國每年約有79.5萬人發生卒中，導致超過14萬人死亡。其中，約40%的卒中相關死亡病例發生在男性，60%發生在女性。 2021年5月發表在《姑息醫學年鑑》（Annals of Palliative Medicine，APM）上的一項研究表明，對服用華法林的急性缺血性卒中（AIS）患者聯合使用四因子凝血酶原複合物濃縮物、新鮮冰凍血漿和維生素K1，可改善其神經功能並成功逆轉凝血功能。因此，卒中發病率的上升是抗凝血逆轉藥物市場的重要促進因素。

新型抗凝血逆轉藥物研究活動日益增加所帶來的機會

為應對心血管疾病（例如心房顫動）日益成長的盛行率，新型療法的研究取得了快速進展，這推動了抗凝血逆轉藥物市場的成長。人們對各種心血管疾病的創新治療方案的需求持續旺盛。例如，2020年7月發表在《血栓與止血雜誌》（Journal of Thrombosis and Haemostasis）上的一項題為“安德沙奈特α和四因子凝血酶原複合物濃縮物（4F-PCC）逆轉利伐沙班和阿哌沙班相關顱內出血的評估”的研究，評估了內安德沙奈特α治療的有效性。研究項目的增加正在促進藥物研發，並為整個行業的市場擴張創造了有利可圖的機會。

抗凝血逆轉藥物市場細分分析

抗凝血逆轉藥物市場分析按產品和配銷通路進行細分。

  • 依產品分類，市場可分為凝血酶原複合物濃縮劑、維生素K、魚精蛋白、氨甲環酸、伊達魯西珠單抗和AndeXXa。 2023年，凝血酶原複合物濃縮劑佔了最大的市場佔有率。
  • 就分銷管道而言，市場分為醫院藥房、零售藥房和其他管道，其中醫院藥房在 2023 年佔據最大的市場佔有率。

抗凝血逆轉藥物市場的地理分析

抗凝血逆轉藥物市場報告的地理範圍分為五個區域：北美、亞太、歐洲、中東和非洲以及南美和中美洲。

北美地區引領抗凝血逆轉藥物市場，其中美國是最大的市場。該地區的成長主要受心血管疾病（如心房顫動）盛行率上升、市場參與者的技術進步以及美國主要公司的存在所驅動，這些因素將進一步加速市場成長。此外，美國市場參與者的策略性舉措預計也將促進市場成長。例如，阿斯特捷利康於2023年6月向美國和歐盟提交了其藥物Andexxa（安德沙奈特α）的完整監管申請，此前該藥物已獲得有條件批准。 Andexxa旨在快速逆轉直介面服FXa抑制劑的抗凝血作用，其使用已獲得15項以上國家和國際指南的支持，涵蓋多個學科領域。阿斯特捷利康目前正在尋求該藥物在美國的完全適應症批准。

抗凝血逆轉藥物市場報告範圍

抗凝血逆轉藥物市場的最新發展

抗凝血逆轉藥物市場評估是透過收集一手和二手研究的定性和定量資料進行的，這些數據包括重要的企業出版物、協會資料和資料庫。以下是言語和語言障礙市場的一些最新進展：

  • 阿斯特捷利康製藥印度有限公司宣布，已獲得印度中央藥品標準控制組織（CDSCO）的批准，可以進口和銷售安德沙奈特α（Andexanet Alfa）。安德沙奈特α是一種治療與Xa因子（FXa）抑制劑相關的危及生命或難治性出血的有效藥物。 （資料來源：阿斯特捷利康製藥，新聞稿，2024）
  • 奧克塔製藥美國公司宣布，其產品Balfaxar已獲得美國食品藥物管理局（FDA）批准。 Balfaxar是一種非活化的四因子凝血酶原複合物濃縮劑（4F-PCC），含有維生素K依賴性凝血因子：凝血因子II（凝血酶原）、凝血因子VII、凝血因子IX和凝血因子X，以及抗血栓蛋白C和S。 Balfaxar適用於因維生素K拮抗劑（VKA）治療而導致後天性凝血因子缺乏的成人患者，這些患者需要緊急手術或介入治療。 Balfaxar透過補充華法林治療引起的凝血因子缺乏，幫助恢復血液凝固功能。 （資料來源：奧克塔製藥美國公司，新聞稿，2023年）

抗凝血逆轉藥物市場報告的覆蓋範圍和交付成果

題為《抗凝血逆轉藥物市場規模及預測（2021-2031）》的報告對市場進行了全面分析，涵蓋以下領域：

  • 涵蓋範圍內所有關鍵細分市場的全球、區域和國家層面的市場規模和預測
  • 市場動態，包括促進因素、限制因素和關鍵機會
  • 未來主要趨勢
  • 詳細的PEST/波特五力模型與SWOT分析
  • 全球及區域市場分析，重點在於關鍵市場趨勢、主要參與者、法規及最新發展。
  • 產業格局和競爭分析，包括市場集中度、熱力圖分析、主要參與者和最新發展動態
  • 深入的公司概況

目錄

第1章：引言

第2章：抗凝血逆轉藥物市場及主要結論

第3章：研究方法

  • 覆蓋範圍
  • 二手研究
  • 初步研究

第4章：抗凝血逆轉藥物市場及市場概況

  • 概述
  • PEST分析
    • 北美和PEST分析
    • 歐洲和PEST分析
    • 亞太地區及PEST分析
    • 中東和非洲
    • 南美洲和中美洲
  • 專家意見

第5章：抗凝血逆轉藥物市場及主要市場動態

  • 市場促進因素
    • 心房顫動（心房顫動）盛行率上升
    • 中風盛行率增加
  • 市場限制
    • 抗凝血逆轉藥物價格昂貴
  • 市場機遇
    • 增加抗凝血逆轉藥物的研究活動
  • 未來趨勢
    • 創新產品的開發與上市
  • 影響分析

第6章：抗凝血逆轉藥物市場及全球分析

  • 全球抗凝血逆轉藥物市場收入預測與分析
  • 全球抗凝血逆轉藥物市場（依地域分類）－預測與分析
  • 市場定位

第7章：抗凝血逆轉藥物市場及產品分類

  • 概述
  • 2024 年及 2031 年抗凝血逆轉藥物市場佔有率（按產品分類）
  • 凝血酶原複合物濃縮物
    • 概述
    • 凝血酶原複合物濃縮劑：抗凝血逆轉藥物市場及收入預測（至2031年）
  • 維生素K
    • 概述
    • 維生素K：抗凝血逆轉藥物市場及收入預測（至2031年）
  • 魚精蛋白
    • 概述
    • 魚精蛋白：抗凝血逆轉藥物市場及收入預測（至2031年）
  • 氨甲環酸
    • 概述
    • 氨甲環酸：抗凝血逆轉藥物市場及收入預測（至2031年）
  • 伊達魯西珠單抗
    • 概述
    • 伊達魯西珠單抗：抗凝血逆轉藥物市場及收入預測（至2031年）
  • 安德克薩
    • 概述
    • Andexxa：抗凝血逆轉藥物市場及收入預測（至2031年）

第8章：抗凝血逆轉藥物市場及配銷通路

  • 概述
  • 2024 年及 2031 年抗凝血逆轉藥物市場佔有率（按配銷通路分類）
  • 醫院藥房
    • 概述
    • 醫院藥局：抗凝血逆轉藥物市場及收入預測（至2031年）
  • 零售藥局
    • 概述
    • 零售藥局：抗凝血逆轉藥物市場及收入預測（至2031年）
  • 其他
    • 概述
    • 其他：抗凝血逆轉藥物市場及收入預測（至2031年）

第9章：抗凝血逆轉藥物市場及地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 亞太其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第10章：新冠肺炎疫情對全球抗凝血逆轉藥物市場的影響

  • 北美洲
  • 歐洲
  • 亞太
  • 中東和非洲
  • 南美洲和中美洲

第11章：抗凝血逆轉藥物市場及產業概況

  • 概述
  • 市場中各公司採取的成長策略（%）
  • 有機發展
    • 概述
    • 公司進行的有機發展
  • 無機物發展
    • 概述
    • 公司進行的非有機成長

第12章：公司簡介

  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Octapharma AG
  • AMAG PHARMACEUTICALS, INC.
  • Fresenius Kabi AG
  • Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
  • CSL Limited
  • China Biologic Products, Inc
  • Grifols, S.A.
  • Shanghai RAAS Blood Products Co., Ltd.

第13章：附錄

簡介目錄
Product Code: TIPRE00004954

The Anticoagulant Reversal Drugs Market is anticipated to grow to US$ 2.44 billion by 2031, up from US$ 1.43 billion in 2024, reflecting a compound annual growth rate (CAGR) of 10.08% from 2031 to 2031. The introduction and launch of innovative products are expected to be significant trends in the anticoagulant reversal drugs market.

Analysis of the Anticoagulant Reversal Drugs Market

Recently, the use of anticoagulants has surged for the prevention and treatment of various cardiovascular issues, including pulmonary embolism (PE), deep vein thrombosis (DVT), atrial fibrillation (AF), thrombosis related to mechanical heart valves, and acute coronary syndromes. However, the extensive use of these medications poses risks of both major and minor bleeding, which can lead to hospital admissions and emergency visits. This risk is heightened when patients are on combination therapies that include both anticoagulants and antiplatelet or dual antiplatelet therapies. Warfarin and aspirin, when used alone, present the highest bleeding risks. Consequently, anticoagulant reversal drugs are essential for mitigating bleeding risks. The increasing prevalence of atrial fibrillation (AFib) and rising stroke incidents are expected to drive the development of new treatments aimed at improving patient outcomes.

Overview of the Anticoagulant Reversal Drugs Market

According to the Centers for Disease Control and Prevention (CDC), over 454,000 hospitalizations related to AFib occur annually in the US, leading to approximately 158,000 deaths. The likelihood of developing AFib increases with age, and high blood pressure, which is also more prevalent in older populations, contributes to about 1 in 5 AFib cases. The growing elderly population is projected to boost the demand for anticoagulant reversal drugs over the next decade.

Strategic Insights

Drivers and Opportunities in the Anticoagulant Reversal Drugs Market

Increasing Incidence of Neurodegenerative Diseases and Speech Disorders

Anticoagulant reversal drugs play a crucial role in managing hemorrhagic strokes by reducing ongoing bleeding and facilitating tissue recovery. The prevalence of strokes is rising, particularly in low- and middle-income countries. The Stroke Awareness Foundation reports that approximately 795,000 people in the US experience a stroke each year, resulting in over 140,000 deaths. Of these, around 40% of stroke-related fatalities occur in men, while 60% are in women. A study published in the Annals of Palliative Medicine (APM) in May 2021 demonstrated that administering a combination of 4-factor prothrombin complex concentrate, fresh frozen plasma, and vitamin K1 to a patient on warfarin who suffered an acute ischemic stroke (AIS) resulted in neurological improvement and successful reversal of coagulation. Thus, the increasing incidence of strokes is a significant driver for the anticoagulant reversal drugs market.

Opportunities from Growing Research Activities in Novel Anticoagulant Reversal Drugs

Rapid advancements in research for new therapeutics to address the rising prevalence of cardiovascular diseases, such as atrial fibrillation, are propelling the growth of the anticoagulant reversal drugs market. There is a continuous demand for innovative treatment options for various cardiovascular conditions. For example, a study titled 'Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages,' published in July 2020 in the Journal of Thrombosis and Haemostasis, assessed the effectiveness of andexanet alfa in treating intracranial hemorrhages (ICH). The rise in research initiatives is enhancing drug discovery efforts and creating lucrative opportunities for market expansion across the sector.

Segmentation Analysis of the Anticoagulant Reversal Drugs Market

The analysis of the anticoagulant reversal drugs market is segmented by product and distribution channel.

  • By product, the market is categorized into prothrombin complex concentrates, vitamin K, protamine, tranexamic acid, idarucizumab, and AndeXXa. The prothrombin complex concentrates segment accounted for the largest market share in 2023.
  • Regarding distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and others, with hospital pharmacies holding the largest market share in 2023.

Geographical Analysis of the Anticoagulant Reversal Drugs Market

The geographical scope of the anticoagulant reversal drugs market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America leads the anticoagulant reversal drugs market, with the US being the largest market. The growth in this region is primarily driven by the increasing prevalence of cardiovascular diseases such as atrial fibrillation, advancements by market players, and the presence of major companies in the US, which will further accelerate market growth. Additionally, strategic initiatives by market players in the US are expected to enhance market growth. For instance, in June 2023, AstraZeneca submitted full regulatory filings for its Andexxa (andexanet alfa) in the US and EU, progressing from its current conditional approval. Andexxa is designed to rapidly reverse the anticoagulation effects of direct oral FXa inhibitors, and its use is supported by over 15 national and international guidelines across various disciplines. AstraZeneca is now pursuing full label approval in the US.

Scope of the Anticoagulant Reversal Drugs Market Report

Recent Developments in the Anticoagulant Reversal Drugs Market

The anticoagulant reversal drugs market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Below are some recent developments in the market for speech and language disorders:

  • AstraZeneca Pharma India Ltd. announced that it received approval from the Central Drugs Standard Control Organisation (CDSCO) in India to import and market Andexanet Alfa, a treatment effective for life-threatening or refractory bleeding associated with Factor Xa (FXa) inhibitors. (Source: AstraZeneca Pharma, Press Release, 2024)
  • Octapharma USA announced the FDA approval of Balfaxar, a non-activated four-factor prothrombin complex concentrate (4F-PCC) containing vitamin K-dependent factors: Factor II (prothrombin), Factor VII, Factor IX, and Factor X, along with antithrombotic Proteins C and S. Balfaxar is indicated for urgent reversal of acquired coagulation factor deficiency due to vitamin K antagonist (VKA) therapy in adult patients requiring urgent surgery or invasive procedures, helping to restore blood coagulation by replenishing deficient clotting factors caused by warfarin therapy. (Source: Octapharma USA, Inc, Press Release, 2023)

Coverage and Deliverables of the Anticoagulant Reversal Drugs Market Report

The report titled "Anticoagulant Reversal Drugs Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

  • Market size and forecast at global, regional, and country levels for all key market segments included in the scope
  • Market dynamics, including drivers, restraints, and key opportunities
  • Key future trends
  • Detailed PEST/Porter's Five Forces and SWOT analysis
  • Global and regional market analysis highlighting key market trends, major players, regulations, and recent developments
  • Industry landscape and competition analysis, including market concentration, heat map analysis, prominent players, and recent developments
  • In-depth company profiles

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Anticoagulant Reversal Drugs Market and By Product
    • 1.3.2 Global Anticoagulant Reversal Drugs Market and By Distribution Channel
    • 1.3.3 Global Anticoagulant Reversal Drugs Market and By Geography

2. Anticoagulant Reversal Drugs Market and Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Anticoagulant Reversal Drugs Market and Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America and PEST Analysis
    • 4.2.2 Europe and PEST Analysis
    • 4.2.3 Asia Pacific and PEST Analysis
    • 4.2.4 Middle East and Africa
    • 4.2.5 South and Central America
  • 4.3 Expert Opinion

5. Anticoagulant Reversal Drugs Market and Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rise in Prevalence of Atrial Fibrillation (AFib)
    • 5.1.2 Increase in Prevalence of Stroke
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Anticoagulant Reversal Drugs
  • 5.3 Market Opportunities
    • 5.3.1 Increasing Research Activities on Anticoagulant Reversal Drugs
  • 5.4 Future Trends
    • 5.4.1 Development and Launch of Innovative Products
  • 5.5 Impact Analysis

6. Anticoagulant Reversal Drugs Market and Global Analysis

  • 6.1 Global Anticoagulant Reversal Drugs Market Revenue Forecast And Analysis
  • 6.2 Global Anticoagulant Reversal Drugs Market, By Geography - Forecast And Analysis
  • 6.3 Market Positioning

7. Anticoagulant Reversal Drugs Marketand By Product

  • 7.1 Overview
  • 7.2 Anticoagulant Reversal Drugs Market Share, by Product, 2024 and 2031 (%)
  • 7.3 Prothrombin Complex Concentrates
    • 7.3.1 Overview
    • 7.3.2 Prothrombin Complex Concentrates: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
  • 7.4 Vitamin K
    • 7.4.1 Overview
    • 7.4.2 Vitamin K: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
  • 7.5 Protamine
    • 7.5.1 Overview
    • 7.5.2 Protamine: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
  • 7.6 Tranexamic Acid
    • 7.6.1 Overview
    • 7.6.2 Tranexamic Acid: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
  • 7.7 Idarucizumab
    • 7.7.1 Overview
    • 7.7.2 Idarucizumab: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
  • 7.8 Andexxa
    • 7.8.1 Overview
    • 7.8.2 Andexxa: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)

8. Anticoagulant Reversal Drugs Marketand By Distribution Channel

  • 8.1 Overview
  • 8.2 Anticoagulant Reversal Drugs Market Share, by Distribution Channel, 2024 and 2031 (%)
  • 8.3 Hospital Pharmacies
    • 8.3.1 Overview
    • 8.3.2 Hospital Pharmacies: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
  • 8.4 Retail Pharmacies
    • 8.4.1 Overview
    • 8.4.2 Retail Pharmacies: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)

9. Anticoagulant Reversal Drugs Market and Geographic Analysis

  • 9.1 North America: Anticoagulant Reversal Drugs Market
    • 9.1.1 Overview
    • 9.1.2 North America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
    • 9.1.3 North America: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
    • 9.1.4 North America: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2024 and 2031 (USD Million)
    • 9.1.5 North America: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
    • 9.1.6 US: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.1.6.1 US: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.1.6.2 US: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
      • 9.1.6.3 US: Anticoagulant Reversal Drugs Market, by Distribution Channel 2024 and 2031 (USD Million)
    • 9.1.7 Canada: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.1.7.1 Canada: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.1.7.2 Canada: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
      • 9.1.7.3 Canada: Anticoagulant Reversal Drugs Market, by Distribution Channel 2024 and 2031 (USD Million)
    • 9.1.8 Mexico: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.1.8.1 Mexico: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.1.8.2 Mexico: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
      • 9.1.8.3 Mexico: Anticoagulant Reversal Drugs Market, by Distribution Channel 2024 and 2031 (USD Million)
  • 9.2 Europe: Anticoagulant Reversal Drugs Market
    • 9.2.1 Overview
    • 9.2.2 Europe: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
    • 9.2.3 Europe: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
    • 9.2.4 Europe: Anticoagulant Reversal Drugs Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.2.5 Europe: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
    • 9.2.6 Germany: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.6.1 Germany: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.6.2 Germany: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.2.6.3 Germany: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.2.7 France: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.7.1 France: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.7.2 France: Anticoagulant Reversal Drugs Market, by Productand Revenue and Forecast to 2031 (USD Million)
      • 9.2.7.3 France: Anticoagulant Reversal Drugs Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.2.8 UK: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.8.1 UK: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.8.2 UK: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.2.8.3 UK: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.2.9 Italy: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.9.1 Italy: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.9.2 Italy: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.2.9.3 Italy: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.2.10 Spain: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.10.1 Spain: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.10.2 Spain: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.2.10.3 Spain: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.2.11 Rest of Europe: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.11.1 Rest of Europe: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.11.2 Rest of Europe: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.2.11.3 Rest of Europe: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
  • 9.3 Asia Pacific: Anticoagulant Reversal Drugs Market
    • 9.3.1 Overview
    • 9.3.2 Asia Pacific: Anticoagulant Reversal Drugs Market - Revenue and Forecast to 2031 (USD Million)
    • 9.3.3 Asia Pacific: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
    • 9.3.4 Asia Pacific: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.3.5 Asia Pacific: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
    • 9.3.6 China: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.6.1 China: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.6.2 China: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.3.6.3 China: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.3.7 Japan: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.7.1 Japan: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.7.2 Japan: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.3.7.3 Japan: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.3.8 India: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.8.1 India: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.8.2 India: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.3.8.3 India: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.3.9 South Korea: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.9.1 South Korea: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.9.2 South Korea: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.3.9.3 South Korea: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.3.10 Australia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.10.1 Australia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.10.2 Australia: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.3.10.3 Australia: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.3.11 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.11.1 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.11.2 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.3.11.3 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
  • 9.4 Middle East and Africa: Anticoagulant Reversal Drugs Market
    • 9.4.1 Overview
    • 9.4.2 Middle East and Africa: Anticoagulant Reversal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    • 9.4.3 Middle East and Africa Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
    • 9.4.4 Middle East and Africa Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.4.5 Middle East and Africa: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
    • 9.4.6 Saudi Arabia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.6.1 Saudi Arabia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.6.2 Saudi Arabia Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.4.6.3 Saudi Arabia Anticoagulant Reversal Drugs Market, Type and Revenue and Forecast to 2031 (USD Million)
    • 9.4.7 UAE: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.7.1 UAE: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.7.2 UAE Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.4.7.3 UAE Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.4.8 South Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.8.1 South Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.8.2 South Africa Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.4.8.3 South Africa Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.4.9 Rest of Middle East and Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.9.1 Rest of Middle East and Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.9.2 Rest of Middle East and Africa Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.4.9.3 Rest of Middle East and Africa Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
  • 9.5 South and Central America: Anticoagulant Reversal Drugs Market
    • 9.5.1 Overview
    • 9.5.2 South and Central America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
    • 9.5.3 South and Central America: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
    • 9.5.4 South and Central America: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.5.5 South and Central America: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
    • 9.5.6 Brazil: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.5.6.1 Brazil: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.5.6.2 Brazil: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.5.6.3 Brazil: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.5.7 Argentina: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.5.7.1 Argentina: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.5.7.2 Argentina: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.5.7.3 Argentina: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.5.8 Rest of South and Central America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.5.8.1 Rest of South and Central America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.5.8.2 Rest of South and Central America: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.5.8.3 Rest of South and Central America: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)

10. Impact of COVID-19 Pandemic on Global Anticoagulant Reversal Drugs Market

  • 10.1 North America: Impact Assessment of COVID-19 Pandemic
  • 10.2 Europe: Impact Assessment of COVID-19 Pandemic
  • 10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
  • 10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
  • 10.5 South and Central America: Impact Assessment of COVID-19 Pandemic

11. Anticoagulant Reversal Drugs Marketand Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies Done by the Companies in the Market, (%)
  • 11.3 Organic Developments
    • 11.3.1 Overview
    • 11.3.2 Organic Developments Done By Companies
  • 11.4 Inorganic Developments
    • 11.4.1 Overview
    • 11.4.2 Inorganic Developments Done By Companies

12. Company Profiles

  • 12.1 Boehringer Ingelheim International GmbH
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Pfizer Inc.
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Octapharma AG
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 AMAG PHARMACEUTICALS, INC.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Fresenius Kabi AG
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 CSL Limited
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 China Biologic Products, Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Grifols, S.A.
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Shanghai RAAS Blood Products Co., Ltd.
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 Glossary of Terms